膵臓がんプレシジョンメディシンの世界市場レポート 2025年

膵臓がんプレシジョンメディシン市場規模は、今後数年で急成長が見込まれます。2029年には10億8,000万米ドルに成長し、CAGRは17.9%となります。予測期間中の成長は、個別化腫瘍学研究への投資の増加、バイオマーカーに基づく診断検査の利用可能性の拡大、標的療法の採用の増加、精密治療の臨床試験のパイプラインの増加、個別化医療に対する規制当局の支援策、バイオテクノロジー企業と研究機関の協力関係の拡大など、いくつかの要因によるものと考えられます。予測期間における主な動向としては、リキッドバイオプシー技術の発展、個別化免疫療法の開発、AI主導の予測分析の採用、新たなバイオマーカー発見の出現、より詳細な腫瘍プロファイリングのためのマルチオミクスアプローチの統合、標的併用療法の台頭などが挙げられます。

膵臓がんの罹患率の増加は、膵臓がんプレシジョンメディシン市場の拡大を促進すると予測されています。消化や血糖値の調節に重要な臓器である膵臓から発生する膵臓がんは、高齢化や肥満、糖尿病、喫煙などの危険因子の有病率の増加などの要因により患者数が増加しています。膵臓がんに対するプレシジョン医療は、遺伝子や分子のデータに基づき、個人に合わせた治療計画を提供することで治療成績を向上させる。このアプローチは治療効果を高め、副作用を最小限に抑えるため、より効率的ながん管理に不可欠なツールとなっています。例えば、2025年2月、Cancer Australiaは、2024年の膵臓がんの新規症例数は4,641例で、男性が2,414例、女性が2,227例で、2023年の3,968例から増加していると報告しました。このように、膵臓がんの罹患率の増加が、この疾患の精密医療市場の成長に寄与しています。

膵臓がんプレシジョンメディシン市場の主要企業は、早期発見を強化し、正確な腫瘍プロファイリングを可能にし、より良い患者の転帰のために個別化された治療戦略を最適化するために、精密医療ツールなどの先進技術の開発にますます注力しています。精密医療ツールとは、個人固有の生物学的特徴に基づいて病気の診断や治療を支援する専門的な装置です。例えば、2024年1月、米国を拠点とするヘルスケア機関であるシーダーズ・サイナイは、モレキュラー・ツイン・プレシジョン・オンコロジー・プラットフォームを立ち上げました。このツールは、重要なバイオマーカーを特定することで、膵臓がんの生存をより正確に予測することを目的としています。このプラットフォームは、74人の膵管腺がん患者から採取した血液と組織サンプルを用いて、より正確で利用しやすいプレシジョン・オンコロジーへのアプローチを提供することで、リソースが限られている地域でも治療方針の決定を導くことができる強い可能性を持っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の膵臓がんプレシジョンメディシンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の膵臓がんプレシジョンメディシン市場：成長率分析
• 世界の膵臓がんプレシジョンメディシン市場の実績：規模と成長, 2019-2024
• 世界の膵臓がんプレシジョンメディシン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の膵臓がんプレシジョンメディシン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膵臓がんプレシジョンメディシン市場：治療アプローチ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 免疫療法
• 化学療法と精密療法の併用
• その他の治療アプローチ
• 世界の膵臓がんプレシジョンメディシン市場：診断技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲノム検査
• 分子診断
• 液体生検
• バイオマーカーベースのコンパニオン診断
• その他の診断技術
• 世界の膵臓がんプレシジョンメディシン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 学術研究機関
• 診断センター
• 世界の膵臓がんプレシジョンメディシン市場、標的療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• キナーゼ阻害剤
• PARP阻害剤
• その他の分子標的薬
• 世界の膵臓がんプレシジョンメディシン市場、免疫療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• がんワクチン
• アダプティブ細胞療法
• その他の免疫療法アプローチ
• 世界の膵臓がんプレシジョンメディシン市場、化学療法と精密療法の併用、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲムシタビンをベースとした併用
• フルオロウラシルベースの併用
• ナブパクリタキセルベースの併用
• その他の化学療法の併用
• 世界の膵臓がんプレシジョンメディシン市場、その他の治療アプローチ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• RNAベースの治療法
• エピジェネティックモジュレーター
• 抗体薬物複合体（ADC）

第7章 地域別・国別分析

• 世界の膵臓がんプレシジョンメディシン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膵臓がんプレシジョンメディシン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膵臓がんプレシジョンメディシン市場：競合情勢
• 膵臓がんプレシジョンメディシン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly and Company
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Genentech Inc.
• Illumina Inc.
• Ipsen Pharma
• Guardant Health
• FOUNDATION MEDICINE INC.
• Oncolytics Biotech Inc.
• Celgene Corporation
• Erytech Pharma
• PharmaCyte Biotech Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膵臓がんプレシジョンメディシン市場2029：新たな機会を提供する国
• 膵臓がんプレシジョンメディシン市場2029：新たな機会を提供するセグメント
• 膵臓がんプレシジョンメディシン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pancreatic cancer precision medicine is a specialized treatment approach that tailors care to individual pancreatic cancer patients. It uses the patient's genetic and molecular information, both from their body and their cancer, to develop a personalized treatment plan. This approach improves patient outcomes by customizing treatment, reducing unnecessary interventions, and increasing the chances of successful outcomes.

The primary therapeutic strategies in pancreatic cancer precision medicine include targeted therapy, immunotherapy, chemotherapy-precision combinations, and others. Targeted therapy involves drugs specifically designed to act on genetic mutations, proteins, or other molecules that contribute to the growth and spread of cancer cells. A variety of diagnostic technologies support these treatments, such as genomic testing, molecular diagnostics, liquid biopsy, and biomarker-based companion diagnostics. These technologies and therapies are applied in settings such as hospitals, specialty clinics, academic and research institutes, and diagnostic centers.

The pancreatic cancer precision medicine market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer precision medicine market statistics, including the pancreatic cancer precision medicine industry global market size, regional shares, competitors with the pancreatic cancer precision medicine market share, detailed pancreatic cancer precision medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the pancreatic cancer precision medicine industry. This pancreatic cancer precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pancreatic cancer precision medicine market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth during the historic period can be attributed to several factors, including the rising incidence of pancreatic cancer, advancements in the understanding of tumor heterogeneity, increased investment in oncology research, greater availability of biomarker-driven therapies, improved diagnostic tools for early detection, and a growing adoption of personalized treatment approaches.

The pancreatic cancer precision medicine market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 17.9%. The growth during the forecast period can be attributed to several factors, including increasing investments in personalized oncology research, greater availability of biomarker-based diagnostic tests, rising adoption of targeted therapies, a growing pipeline of clinical trials for precision treatments, supportive regulatory initiatives for personalized medicine, and expanding collaborations between biotech companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of personalized immunotherapies, the adoption of AI-driven predictive analytics, the emergence of new biomarker discoveries, the integration of multi-omics approaches for more detailed tumor profiling, and the rise of targeted combination therapies.

The growing incidence of pancreatic cancer is anticipated to drive the expansion of the pancreatic cancer precision medicine market. Pancreatic cancer, which begins in the pancreas-an organ crucial for digestion and blood sugar regulation-has seen a rise in cases due to factors such as an aging population and the increasing prevalence of risk factors such as obesity, diabetes, and smoking. Precision medicine for pancreatic cancer improves treatment outcomes by providing personalized treatment plans based on genetic and molecular data. This approach enhances treatment effectiveness and minimizes side effects, making it an essential tool for more efficient cancer management. For example, in February 2025, Cancer Australia reported that there were 4,641 new cases of pancreatic cancer in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. As such, the growing incidence of pancreatic cancer is contributing to the growth of the precision medicine market for this disease.

Leading companies in the pancreatic cancer precision medicine market are increasingly focusing on developing advanced technologies, such as precision medical tools, to enhance early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for better patient outcomes. Precision medical tools are specialized devices that assist in diagnosing and treating diseases based on an individual's unique biology. For instance, in January 2024, Cedars-Sinai, a U.S.-based healthcare organization, launched the molecular twin precision oncology platform. This tool aims to more accurately predict pancreatic cancer survival by identifying key biomarkers. The platform has strong potential for guiding treatment decisions, even in areas with limited resources, by using blood and tissue samples from 74 pancreatic ductal adenocarcinoma patients to provide a more precise and accessible approach to precision oncology.

In September 2022, Oncodesign Precision Medicine (OPM), a biotechnology firm based in France, entered into a collaboration with Servier Laboratories to identify and validate new therapeutic targets in pancreatic ductal adenocarcinoma (PDAC). This collaboration seeks to accelerate the development of precision medicine for cancer treatment by combining OPM's expertise in biomarkers and therapeutic solutions with Servier's oncology research and drug development capabilities. Servier Laboratories is a French pharmaceutical company specializing in treatments for oncology and immuno-inflammatory diseases.

Major players in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, Eli Lilly and Company, Amgen Inc, Teva Pharmaceutical Industries Ltd, Genentech Inc., Illumina Inc., Ipsen Pharma, Guardant Health, FOUNDATION MEDICINE INC., Oncolytics Biotech Inc., Celgene Corporation, Erytech Pharma, PharmaCyte Biotech Inc.

North America was the largest region in the pancreatic cancer precision medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pancreatic cancer precision medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic cancer precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic cancer precision medicine market includes revenues earned by entities by providing services such as personalized treatment planning, tumour molecular profiling, precision imaging and diagnostics, and targeted therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic cancer precision medicine market consists of sales of genetic and biomarker testing kits, immunotherapy drugs, and personalized cancer vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Precision Medicine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer precision medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer precision medicine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer precision medicine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Approach: Targeted Therapy; Immunotherapy; Chemotherapy-Precision Combinations; Other Therapeutic Approache
• 2) By Diagnostic Technology: Genomic Testing; Molecular Diagnostics; Liquid Biopsy; Biomarker-Based Companion Diagnostics; Other Diagnostic Technologies
• 3) By Application: Hospitals; Specialty Clinics; Academic And Research Institutes; Diagnostic Centers
• Subsegments:
• 1) By Targeted Therapy: Kinase Inhibitors; PARP Inhibitors; Other Molecular Targeted Agents
• 2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Adoptive Cell Therapy; Other Immunotherapy Approaches
• 3) By Chemotherapy-Precision Combinations: Gemcitabine-Based Combinations; Fluorouracil-Based Combinations; Nab-Paclitaxel-Based Combinations; Other Chemotherapy Combinations
• 4) By Other Therapeutic Approaches: RNA-Based Therapies; Epigenetic Modulators; Antibody-Drug Conjugates (ADCs); Other Innovative Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Precision Medicine Market Characteristics

3. Pancreatic Cancer Precision Medicine Market Trends And Strategies

4. Pancreatic Cancer Precision Medicine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pancreatic Cancer Precision Medicine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pancreatic Cancer Precision Medicine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pancreatic Cancer Precision Medicine Market Growth Rate Analysis
• 5.4. Global Pancreatic Cancer Precision Medicine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pancreatic Cancer Precision Medicine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pancreatic Cancer Precision Medicine Total Addressable Market (TAM)

6. Pancreatic Cancer Precision Medicine Market Segmentation

• 6.1. Global Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy-Precision Combinations
• Other Therapeutic Approaches
• 6.2. Global Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genomic Testing
• Molecular Diagnostics
• Liquid Biopsy
• Biomarker-Based Companion Diagnostics
• Other Diagnostic Technologies
• 6.3. Global Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Academic And Research Institutes
• Diagnostic Centers
• 6.4. Global Pancreatic Cancer Precision Medicine Market, Sub-Segmentation Of Targeted Therapy By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kinase Inhibitors
• PARP Inhibitors
• Other Molecular Targeted Agents
• 6.5. Global Pancreatic Cancer Precision Medicine Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Adoptive Cell Therapy
• Other Immunotherapy Approaches
• 6.6. Global Pancreatic Cancer Precision Medicine Market, Sub-Segmentation Of Chemotherapy-Precision Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gemcitabine-Based Combinations
• Fluorouracil-Based Combinations
• Nab-Paclitaxel-Based Combinations
• Other Chemotherapy Combinations
• 6.7. Global Pancreatic Cancer Precision Medicine Market, Sub-Segmentation Of Other Therapeutic Approaches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA-Based Therapies
• Epigenetic Modulators
• Antibody-Drug Conjugates (ADCs)

7. Pancreatic Cancer Precision Medicine Market Regional And Country Analysis

• 7.1. Global Pancreatic Cancer Precision Medicine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pancreatic Cancer Precision Medicine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pancreatic Cancer Precision Medicine Market

• 8.1. Asia-Pacific Pancreatic Cancer Precision Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pancreatic Cancer Precision Medicine Market

• 9.1. China Pancreatic Cancer Precision Medicine Market Overview
• 9.2. China Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pancreatic Cancer Precision Medicine Market

• 10.1. India Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pancreatic Cancer Precision Medicine Market

• 11.1. Japan Pancreatic Cancer Precision Medicine Market Overview
• 11.2. Japan Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pancreatic Cancer Precision Medicine Market

• 12.1. Australia Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pancreatic Cancer Precision Medicine Market

• 13.1. Indonesia Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pancreatic Cancer Precision Medicine Market

• 14.1. South Korea Pancreatic Cancer Precision Medicine Market Overview
• 14.2. South Korea Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pancreatic Cancer Precision Medicine Market

• 15.1. Western Europe Pancreatic Cancer Precision Medicine Market Overview
• 15.2. Western Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pancreatic Cancer Precision Medicine Market

• 16.1. UK Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pancreatic Cancer Precision Medicine Market

• 17.1. Germany Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pancreatic Cancer Precision Medicine Market

• 18.1. France Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pancreatic Cancer Precision Medicine Market

• 19.1. Italy Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pancreatic Cancer Precision Medicine Market

• 20.1. Spain Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pancreatic Cancer Precision Medicine Market

• 21.1. Eastern Europe Pancreatic Cancer Precision Medicine Market Overview
• 21.2. Eastern Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pancreatic Cancer Precision Medicine Market

• 22.1. Russia Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pancreatic Cancer Precision Medicine Market

• 23.1. North America Pancreatic Cancer Precision Medicine Market Overview
• 23.2. North America Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pancreatic Cancer Precision Medicine Market

• 24.1. USA Pancreatic Cancer Precision Medicine Market Overview
• 24.2. USA Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pancreatic Cancer Precision Medicine Market

• 25.1. Canada Pancreatic Cancer Precision Medicine Market Overview
• 25.2. Canada Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pancreatic Cancer Precision Medicine Market

• 26.1. South America Pancreatic Cancer Precision Medicine Market Overview
• 26.2. South America Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pancreatic Cancer Precision Medicine Market

• 27.1. Brazil Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pancreatic Cancer Precision Medicine Market

• 28.1. Middle East Pancreatic Cancer Precision Medicine Market Overview
• 28.2. Middle East Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pancreatic Cancer Precision Medicine Market

• 29.1. Africa Pancreatic Cancer Precision Medicine Market Overview
• 29.2. Africa Pancreatic Cancer Precision Medicine Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pancreatic Cancer Precision Medicine Market, Segmentation By Diagnostic Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pancreatic Cancer Precision Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pancreatic Cancer Precision Medicine Market Competitive Landscape And Company Profiles

• 30.1. Pancreatic Cancer Precision Medicine Market Competitive Landscape
• 30.2. Pancreatic Cancer Precision Medicine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Pancreatic Cancer Precision Medicine Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. AstraZeneca Plc
• 31.3. Novartis AG
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc
• 31.6. Teva Pharmaceutical Industries Ltd
• 31.7. Genentech Inc.
• 31.8. Illumina Inc.
• 31.9. Ipsen Pharma
• 31.10. Guardant Health
• 31.11. FOUNDATION MEDICINE INC.
• 31.12. Oncolytics Biotech Inc.
• 31.13. Celgene Corporation
• 31.14. Erytech Pharma
• 31.15. PharmaCyte Biotech Inc.

32. Global Pancreatic Cancer Precision Medicine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Cancer Precision Medicine Market

34. Recent Developments In The Pancreatic Cancer Precision Medicine Market

35. Pancreatic Cancer Precision Medicine Market High Potential Countries, Segments and Strategies

• 35.1 Pancreatic Cancer Precision Medicine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pancreatic Cancer Precision Medicine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pancreatic Cancer Precision Medicine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer